Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 19
2003 18
2004 26
2005 23
2006 25
2007 23
2008 33
2009 39
2010 46
2011 36
2012 43
2013 46
2014 57
2015 52
2016 68
2017 71
2018 81
2019 91
2020 174
2021 190
2022 177
2023 170
2024 171
2025 154
2026 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,597 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampé R, Zhu H, Oaknin A, Christiaens M, Polterauer S, Usami T, Li K, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators. Lorusso D, et al. Among authors: scambia g. Lancet. 2024 Apr 6;403(10434):1341-1350. doi: 10.1016/S0140-6736(24)00317-9. Epub 2024 Mar 20. Lancet. 2024. PMID: 38521086 Clinical Trial.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Cvek J, Randall L, Pereira de Santana Gomes AJ, Contreras Mejía F, Helpman L, Akıllı H, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Colombo N, Chang CL, Bednarikova M, Zhu H, Oaknin A, Christiaens M, Petru E, Usami T, Liu P, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators. Lorusso D, et al. Among authors: scambia g. Lancet. 2024 Oct 5;404(10460):1321-1332. doi: 10.1016/S0140-6736(24)01808-7. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288779 Clinical Trial.
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN; SOLO1 Investigators. DiSilvestro P, et al. Among authors: scambia g. J Clin Oncol. 2023 Jan 20;41(3):609-617. doi: 10.1200/JCO.22.01549. Epub 2022 Sep 9. J Clin Oncol. 2023. PMID: 36082969 Free PMC article. Clinical Trial.
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. Among authors: scambia g. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
Lifestyle and diet in PCOS.
Capozzi A, Scambia G, Driul L, Vignali M, Lello S. Capozzi A, et al. Among authors: scambia g. Minerva Obstet Gynecol. 2025 Oct;77(5):341-351. doi: 10.23736/S2724-606X.25.05746-X. Epub 2025 Oct 1. Minerva Obstet Gynecol. 2025. PMID: 41032353 Free article. Review.
Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE.
Morice P, Scambia G, Abu-Rustum NR, Acien M, Arena A, Brucker S, Cheong Y, Collinet P, Fanfani F, Filippi F, Eriksson AGZ, Gouy S, Harter P, Matias-Guiu X, Pados G, Pakiz M, Querleu D, Rodolakis A, Rousset-Jablonski C, Stepanyan A, Testa AC, Macklon KT, Tsolakidis D, De Vos M, Planchamp F, Grynberg M. Morice P, et al. Among authors: scambia g. Lancet Oncol. 2024 Nov;25(11):e602-e610. doi: 10.1016/S1470-2045(24)00262-6. Epub 2024 Aug 28. Lancet Oncol. 2024. PMID: 39216500
Endometrial carcinosarcoma.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Caruso G, Enomoto T, Takehara K, Denys H, Lorusso D, Coleman R, Vaughan MM, Takano M, Provencher DM, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Kim JW, Candido Dos Reis FJ, Ramirez PT, Mariani A, Leitao M, Makker V, Abu-Rustum NR, Vergote I, Zannoni G, Tan D, McCormack M, Paolini B, Bini M, Raspagliesi F, Benedetti Panici P, Di Donato V, Muzii L, Colombo N, Pignata S, Scambia G, Monk BJ. Bogani G, et al. Among authors: scambia g. Int J Gynecol Cancer. 2023 Feb 6;33(2):147-174. doi: 10.1136/ijgc-2022-004073. Int J Gynecol Cancer. 2023. PMID: 36585027 Free article. Review.
Uterine leiomyosarcoma.
Bogani G, Caruso G, Ray-Coquard I, Ramirez PT, Concin N, Ngoi NY, Coleman RL, Mariani A, Cliby W, Leitao MM Jr, Rustum NA, Casali PG, Gronchi A, Vergote I, Kroep J, Enomoto T, Takehara K, Denys H, Takano M, Provencher D, Wimberger P, Kim SI, Kim JW, Zannoni GF, Tan DS, Casarin J, Paolini B, Chiappa V, Raspagliesi F, Cuccu I, Di Donato V, O'Malley DM, Mutch D, Brown J, Herrera F, Colombo N, Pignata S, Scambia G, Slomovitz BM, Monk BJ. Bogani G, et al. Among authors: scambia g. Int J Gynecol Cancer. 2025 Sep;35(9):101992. doi: 10.1016/j.ijgc.2025.101992. Epub 2025 Jun 30. Int J Gynecol Cancer. 2025. PMID: 40743869 Review.
Pathophysiology and diagnostic criteria of PCOS.
Capozzi A, Vignali M, Scambia G, Lello S. Capozzi A, et al. Among authors: scambia g. Minerva Obstet Gynecol. 2025 Oct;77(5):361-372. doi: 10.23736/S2724-606X.24.05612-4. Epub 2025 Jan 30. Minerva Obstet Gynecol. 2025. PMID: 39883425 Free article. Review.
1,597 results